Clinical Trial: Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)

U.S., Sept. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07193953) titled 'Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)' on May 12.

Brief Summary: The goal of this study is to evaluate the safety and feasibility of IVIg administration in conjunction with primary motor cortex BBB opening using the Next Generation Dome Helmet (NGDH) FUS in adult participants with ALS.

Study Start Date: April 15

Study Type: INTERVENTIONAL

Condition: Amyotrophic Lateral Sclerosis ALS

Intervention: DEVICE: Next Generation Dome Helmet Focused Ultrasound

Two doses of IVIg will be administered 2 weeks apart. The first dose at Week 0 will be a standalone adminis...